Introduction: Non-steroidal anti-inflammatory drug-exacerbated respiratory disease (N-ERD) is heterogeneous in both phenotypes and endotypes. Due to insufficient head-to-head comparison studies, it is hard to decide which biological to initiate. This study aimed to compare the efficacy of omalizumab and mepolizumab which can be used in the treatment of patients with severe eosinophilic asthma diagnosed with N-ERD. Methods: The population of this observational, cross-sectional study comprised of N-ERD patients who received omalizumab or mepolizumab for at least 6 months for severe asthma. Outcomes included the asthma control test (ACT), and sino-nasal outcome test scores (SNOT-22), blood eosinophil counts at initiation of biological treatment (T0, baseline) and at the end of 6th months (T6). Adverse effects related to biological treatment and changes of oral corticosteroids dose was recorded. Results: The study included a total of 22 patients, of whom 11 received mepolizumab and 11 received omalizumab. The change in ACT, SNOT-22, eosinophil counts, and adverse effects related to biologicals were similar at T6 (p = 0.606, p = 0.168, p = 0.05, p = 0.053, respectively). However, when examining the SNOT-22 and ACT based on the cumulative distribution curve (SUCRA), mepolizumab (SUCRA value: 0.61, 0.72, respectively) demonstrated greater efficacy compared to omalizumab (SUCRA value: 0.19, 0.35, respectively). The oral corticosteroids discontinuation rate was similar between the two groups (p = 0.05). Conclusion: We found both omalizumab and mepolizumab to be effective in treatment; however, we determined that mepolizumab may have a potential superiority in efficacy.

1.
Kowalski
ML
,
Agache
I
,
Bavbek
S
,
Bakirtas
A
,
Blanca
M
,
Bochenek
G
, et al
.
Diagnosis and management of NSAID-Exacerbated Respiratory Disease (N-ERD)–a EAACI position paper
.
Allergy
.
2019
;
74
(
1
):
28
39
.
2.
Agache
I
,
Song
Y
,
Rocha
C
,
Beltran
J
,
Posso
M
,
Steiner
C
, et al
.
Efficacy and safety of treatment with dupilumab for severe asthma: a systematic review of the EAACI guidelines–recommendations on the use of biologicals in severe asthma
.
Allergy
.
2020
;
75
(
5
):
1058
68
.
3.
Eschenbacher
W
,
Straesser
M
,
Knoeddler
A
,
Li
R-C
,
Borish
L
.
Biologics for the treatment of allergic rhinitis, chronic rhinosinusitis, and nasal polyposis
.
Immunol Allergy Clin North Am
.
2020
;
40
(
4
):
539
47
.
4.
Tran
TN
,
Zeiger
RS
,
Peters
SP
,
Colice
G
,
Newbold
P
,
Goldman
M
, et al
.
Overlap of atopic, eosinophilic, and TH2-high asthma phenotypes in a general population with current asthma
.
Ann Allergy Asthma Immunol
.
2016
;
116
(
1
):
37
42
.
5.
Fahy
JV
.
Anti-IgE: lessons learned from effects on airway inflammation and asthma exacerbation
.
J Allergy Clin Immunol
.
2006
;
117
(
6
):
1230
2
.
6.
Bavaro
N
,
Gakpo
D
,
Mittal
A
,
Bensko
JC
,
Laidlaw
TM
,
Buchheit
KM
.
Efficacy of dupilumab in patients with aspirin-exacerbated respiratory disease and previous inadequate response to anti-IL-5 or anti-IL-5Rα in a real-world setting
.
J Allergy Clin Immunol Pract
.
2021
;
9
(
7
):
2910
2. e1
.
7.
Bochenek
G
,
Kuschill-Dziurda
J
,
Szafraniec
K
,
Plutecka
H
,
Szczeklik
A
,
Nizankowska-Mogilnicka
E
.
Certain subphenotypes of aspirin-exacerbated respiratory disease distinguished by latent class analysis
.
J Allergy Clin Immunol
.
2014
;
133
(
1
):
98
103.e1-6
.
8.
Agache
I
,
Akdis
CA
,
Akdis
M
,
Canonica
GW
,
Casale
T
,
Chivato
T
, et al
.
EAACI biologicals guidelines–recommendations for severe asthma
.
Allergy
.
2021
;
76
(
1
):
14
44
.
9.
Global Initiative for Asthma
.
Global strategy for asthma management and prevention
.
GINA
;
2022
.
10.
Nathan
RA
,
Sorkness
CA
,
Kosinski
M
,
Schatz
M
,
Li
JT
,
Marcus
P
, et al
.
Development of the asthma control test: a survey for assessing asthma control
.
J Allergy Clin Immunol
.
2004
;
113
(
1
):
59
65
.
11.
Liu
M
,
Liu
J
,
Weitzel
EK
,
Chen
PG
.
The predictive utility of the 22-item sino-nasal outcome test (SNOT-22): a scoping review
.
Int Forum Allergy Rhinol
;
2022
;
12
(
1
):
83
102
.
12.
Cockle
SM
,
Stynes
G
,
Gunsoy
NB
,
Parks
D
,
Alfonso-Cristancho
R
,
Wex
J
, et al
.
Comparative effectiveness of mepolizumab and omalizumab in severe asthma: an indirect treatment comparison
.
Respir Med
.
2017
;
123
:
140
8
.
13.
Wu
Q
,
Zhang
Y
,
Kong
W
,
Wang
X
,
Yuan
L
,
Zheng
R
, et al
.
Which is the best biologic for nasal polyps: dupilumab, omalizumab, or mepolizumab? A network meta-analysis
.
Int Arch Allergy Immunol
.
2022
;
183
(
3
):
279
88
.
14.
Sahota
J
,
Bidder
T
,
Livingston
R
,
Robinson
DS
,
Lund
VJ
,
Su
MP
, et al
.
Chronic rhinosinusitis and omalizumab: eosinophils not IgE predict treatment response in real-life
.
Rhinology
.
2018
;
1
(
1
):
147
53
.
15.
Han
JK
,
Bachert
C
,
Fokkens
W
,
Desrosiers
M
,
Wagenmann
M
,
Lee
SE
, et al
.
Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial
.
Lancet Respir Med
.
2021
;
9
(
10
):
1141
53
.
You do not currently have access to this content.